S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)
S&P 500   5,167.99 (-0.60%)
DOW   38,215.32 (-0.63%)
QQQ   441.23 (-0.93%)
AAPL   176.29 (+0.71%)
MSFT   423.74 (-0.98%)
META   514.83 (-1.59%)
GOOGL   159.67 (+0.16%)
AMZN   187.89 (-0.61%)
TSLA   172.49 (-1.21%)
NVDA   889.35 (-1.86%)
AMD   163.50 (-4.11%)
NIO   4.26 (-4.48%)
BABA   72.65 (-2.94%)
T   16.44 (+0.12%)
F   12.86 (-1.38%)
MU   124.65 (-2.24%)
GE   155.82 (-1.00%)
CGC   8.36 (+2.58%)
DIS   115.99 (-0.99%)
AMC   2.75 (-1.79%)
PFE   26.30 (-0.15%)
PYPL   65.52 (-0.43%)
XOM   123.26 (+1.21%)

CRISPR Therapeutics (CRSP) Competitors

$61.70
-1.21 (-1.92%)
(As of 09:46 AM ET)

CRSP vs. KRYS, HALO, IMVT, IBRX, IOVA, PCVX, APGE, EXEL, SWTX, and ACLX

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Krystal Biotech (KRYS), Halozyme Therapeutics (HALO), Immunovant (IMVT), ImmunityBio (IBRX), Iovance Biotherapeutics (IOVA), Vaxcyte (PCVX), Apogee Therapeutics (APGE), Exelixis (EXEL), SpringWorks Therapeutics (SWTX), and Arcellx (ACLX). These companies are all part of the "biological products, except diagnostic" industry.

CRISPR Therapeutics vs.

CRISPR Therapeutics (NASDAQ:CRSP) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

CRISPR Therapeutics' return on equity of -8.09% beat Krystal Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR TherapeuticsN/A -8.09% -6.73%
Krystal Biotech N/A -13.31%-12.61%

CRISPR Therapeutics received 180 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.59% of users gave Krystal Biotech an outperform vote while only 65.56% of users gave CRISPR Therapeutics an outperform vote.

CompanyUnderperformOutperform
CRISPR TherapeuticsOutperform Votes
455
65.56%
Underperform Votes
239
34.44%
Krystal BiotechOutperform Votes
275
66.59%
Underperform Votes
138
33.41%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 17.0% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

CRISPR Therapeutics presently has a consensus price target of $74.75, indicating a potential upside of 18.82%. Krystal Biotech has a consensus price target of $157.67, indicating a potential downside of 12.38%. Given CRISPR Therapeutics' higher probable upside, research analysts plainly believe CRISPR Therapeutics is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
2 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.41
Krystal Biotech
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

Krystal Biotech has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$370M13.65-$153.61M-$1.96-32.10
Krystal Biotech$50.70M101.20$10.93M$0.082,249.25

In the previous week, CRISPR Therapeutics had 15 more articles in the media than Krystal Biotech. MarketBeat recorded 16 mentions for CRISPR Therapeutics and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.39 beat CRISPR Therapeutics' score of 0.39 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
CRISPR Therapeutics Neutral
Krystal Biotech Neutral

Summary

Krystal Biotech beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$5.05B$2.77B$5.06B$7.77B
Dividend YieldN/A2.23%2.95%3.87%
P/E Ratio-32.109.76264.1519.29
Price / Sales13.65372.832,382.82105.64
Price / CashN/A144.2335.7332.14
Price / Book2.654.064.704.40
Net Income-$153.61M-$37.11M$104.47M$214.97M
7 Day Performance-3.30%-1.10%-0.78%-0.44%
1 Month Performance-18.11%-2.38%-0.91%-0.27%
1 Year Performance38.54%24.99%18.34%11.41%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRYS
Krystal Biotech
3.6197 of 5 stars
$179.77
-0.4%
$157.67
-12.3%
+115.1%$5.13B$50.70M2,247.41229
HALO
Halozyme Therapeutics
4.9928 of 5 stars
$40.13
+0.6%
$53.29
+32.8%
+7.0%$5.10B$829.25M19.02373
IMVT
Immunovant
2.5032 of 5 stars
$31.17
+2.1%
$48.00
+54.0%
+109.7%$4.53BN/A-16.94164Insider Selling
Analyst Revision
News Coverage
IBRX
ImmunityBio
0.0801 of 5 stars
$6.16
-0.2%
$5.00
-18.8%
+293.5%$4.17B$620,000.00-5.31628
IOVA
Iovance Biotherapeutics
4.7662 of 5 stars
$13.22
+1.1%
$24.64
+86.4%
+139.8%$3.69B$1.19M-7.03557Positive News
PCVX
Vaxcyte
0.9196 of 5 stars
$64.51
+0.7%
$78.50
+21.7%
+87.0%$6.99BN/A-15.62254Analyst Report
APGE
Apogee Therapeutics
0.517 of 5 stars
$56.37
+3.2%
$71.83
+27.4%
N/A$3.29BN/A0.0091Short Interest ↑
News Coverage
EXEL
Exelixis
4.992 of 5 stars
$23.72
+1.6%
$26.29
+10.8%
+12.8%$7.19B$1.83B37.061,310Analyst Report
Short Interest ↓
Analyst Revision
SWTX
SpringWorks Therapeutics
2.7608 of 5 stars
$44.22
+0.4%
$68.00
+53.8%
+81.4%$3.26B$5.45M-8.60305News Coverage
Positive News
ACLX
Arcellx
1.9899 of 5 stars
$60.56
-0.2%
$74.17
+22.5%
+109.0%$3.20B$110.32M-41.20130Analyst Report

Related Companies and Tools

This page (NASDAQ:CRSP) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners